

# Arbeitsgruppensitzung Autoimmunbullöse Dermatosen

im Rahmen der virtuellen ADF-Tagung 2021

Donnerstag, den 04.03.2021 von 8:00 bis 12:30 Uhr

(10 Minuten pro Referat einschl. Diskussion!)

## Meeting-Link:

<https://uk-erlangen.webex.com/uk-erlangen/j.php?MTID=m6dff182904163dc92a23ba459bdd92bb>

bzw. <https://webex.com> (Meeting-Kennnummer: 181 119 6624, Passwort: qMMVVZBe828)

**Begrüßung, Technik-Check**  
Michael Sticherling, Erlangen

## Pathogenese

### **Artificial 3D human skin for translational and diagnostic utilization (P141)**

P. Kunth, C. Czyz, F. Gruber, K. Kalies, C. Kremslehner, E. Schmidt, D. Zillikens, C. Hammers, J. Hundt; Luebeck, Vienna

### **Investigating pemphigus vulgaris pathogenesis using a human skin organ culture model (P114)**

H. Asmussen, P. Kastl, N. Feldmann, C. Hammers, D. Zillikens, R. Ludwig, U. auf dem Keller, J. Hundt; Luebeck, Kgs. Lyngby

### **Establishing CD154 as a novel activation marker for detection of autoreactive T cells in pemphigus vulgaris (P045)**

Polakova, L. Kauter, A. Ismagambetova, C. Moebs, C. Hudemann; Marburg

### **ARG1+ IL10+ polymorphonuclear myeloid-derived suppressor cells are elevated in patients with active pemphigus and correlate with an increased Th2 response (P108)**

D. Neri, M. Carevic-Neri, J. Brueck, J. Holstein, I. Schaefer, F. Solimani, D. Hartl, K. Ghoreschi; Berlin, Tuebingen

### **Genetic C5AR1 variant and C5A levels associated with Pemphigus (P122)**

V. Bumiller-Bini, R. Misunori Nisihara, T. Della Justina Farias, E. Lueders, H. Busch, A. Franke, M. Wittig, N. van Beek, D. Zillikens, E. Schmidt, M. Petzl-Erler, J. Hundt, A. Winter Boldt; Curitiba, Luebeck, Kiel

### **Cellular expression of complement receptors C5aR1 and C5aR2 in pemphigoid diseases (P064)**

R. Stahlkopf, S. Emtenani, D. Zillikens, C. Karsten, E. Schmidt; Luebeck

### **Selective PI3K-delta inhibition normalizes aberrant kinase activity in the skin and has therapeutic effects in experimental models of pemphigoid diseases (P068)**

S. Ghorbanalipoor, S. Emtenani, K. Izumi, M. Kamaguchi, I. Osman, J. Hobusch, K. Bieber, L. Chakievska, M. Pigors, A. Wobig, M. Parker, P. Smith, E. Schmidt, R. Ludwig; Luebeck, Sapporo, Wilmington, Delaware

### **Initial analysis of T cell receptor (TCR)? repertoires in perilesional skin biopsies of bullous pemphigoid patients (P148)**

A. Faehnrich, M. Niebuhr, M. Olbrich, H. Busch, E. Schmidt, C. Sadik, D. Zillikens, S. Ibrahim, C. Hammers, K. Kalies; Luebeck

### **Absence of functional Tregs in scurfy mice leads to blister inducing autoantibody directed against Type VII Collagen (P104)**

E. Vicari, S. Haeberle, V. Bolduan, A. Vorobyev, S. Goletz, H. Iwata, R. Ludwig, E. Schmidt, H. Shimizu, A. Enk, E. Hadaschik; Heidelberg, Luebeck, Sapporo, Essen

### **Characterization of skin-resident T cells in pemphigus vulgaris in humans**

C.L. Zimmer, A. Polakova, D. Didona, J. Hinterseher, L. Zwioerek, C. Möbs, W. Pfützner, M. Hertl, Marburg

### **Flotillins as regulators of desmosomal adhesion**

B. Beckert, Antje Banning, Ritva Tikkanen; Gießen

### **The role of caspases in antibody-induced acantholysis**

M.F. Schmidt, M. Feoktistova, R.A. Eichkorn, J.M. Baron, A.S. Yazdi  
Aachen, Tübingen

### **The integral role of Ca<sup>2+</sup> flux-mediated signalling in the epidermal pathology of pemphigus**

T. Schmitt, D. T. Egu, E. Walter, A.M. Sigmund, R. Eichkorn, A. Yazdi, E. Schmidt, M. Sárdy, R. Eming, M. Goebeler, J. Waschke. München, Tübingen, Aachen, Lübeck, Budapest, Marburg. Würzburg

## **Diagnostik**

### **IgG autoantibody responses against desmoglein 3 and bullous pemphigoid 180 in lichen planus (P236)**

D. Didona, R. Pollmann, F. Solimani, R. Eming, M. Hertl; Marburg, Berlin, Koblenz

### **Diagnosis of epidermolysis bullosa acquisita: Comparison of different assays for serum anti-type VII collagen reactivity (P118)**

M. Holtsche, N. van Beek, T. Hashimoto, G. Di Zenzo, D. Zillikens, C. Prost-Squarcioni, M. Titeux, A. Hovnanian, E. Schmidt, S. Goletz; Luebeck, Osaka, Rome, Bobigny, Paris

## **Klinik**

### **The risk of Coronavirus disease 2019 (COVID-19) in patients with bullous pemphigoid and pemphigus: A population-based cohort study (P083)**

K. Kridin, J. Hundt, R. Ludwig, E. Schmidt, Y. Schoenman, A. Cohen; Luebeck, Tel-Aviv

### **Site- and autoantigen- specific associations in mucous membrane pemphigoid lessons learned from a retrospective bicentric observational study (P049)**

N. van Beek, K. Kridin, E. Buehler, A. Kochan, S. Staender, R. Ludwig, I. Koenig, D. Zillikens, C. Guenther, E. Schmidt; Luebeck, Dresden

### **Anxiety and depression predispose individuals to bullous pemphigoid- A largescale population-based cohort study (P081)**

K. Kridin, J. Hundt, R. Ludwig, A. Cohen; Luebeck, Tel-Aviv

### **The influence of complement on the clinical, immunological, and histological features of patients with bullous pemphigoid? Insights from a retrospective cohort study (P082)**

S. Staender, M. Holtsche, E. Schmidt, C. Hammers, D. Zillikens, R. Ludwig, K. Kridin; Luebeck

## **Therapie**

### **Individual treatment heterogeneity in pemphigus patients - a retrospective analysis**

R. Scarpone et al., Berlin, Kiel

### **Targeted inhibition of complement at the basement-membrane zone in bullous pemphigoid (P111)**

C. Hammers, S. Emtenani, O. Isken, N. Tautz, C. Lin, J. Hundt, E. Schmidt, D. Siegel, J. Stanley; Luebeck, Philadelphia

### **Inhibition of phosphodiesterase-4 reverses anti-laminin 332 IgG mediated signal transducing events and functional alterations in vitro (P115)**

S. Tofern, A. Schoelzel, S. Goletz, D. Zillikens, E. Schmidt; Luebeck

### **Successful treatment of recalcitrant pemphigus vulgaris with the phosphodiesterase 4 inhibitor apremilast (P050)**

K. Meier, J. Holstein, F. Solimani, J. Waschke, K. Ghoreschi; Berlin, Tuebingen, Munich

### **Inhibiting acantholysis in pemphigus vulgaris by novel systemic and topical therapeutics (P150)**

U. Radine, V. Bumiller-Bini, H. Asmussen, H. Busch, D. Zillikens, C. Hammers, R. Ludwig, J. Hundt; Luebeck, Curitiba